Cost-utility of treatment of the patients with Thalassemia Major in Iran
Journal Title: Khoon - Year 2019, Vol 15, Issue 4
Abstract
Cost-utility of treatment of the patients with Thalassemia Major in Iran Emamgholipour S.1, Ahmadi B.1, Rajabi A.2, Azarkeivan A.3,4, Ebrahimi M.3,4, Esmaeilzadeh F.5 1School of Public Health, Tehran University of Medical Sciences, Tehran, Iran 2Golestan University of Medical Sciences, Gorgan, Iran 3Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran 4Adult Thalassemia Clinic, Tehran, Iran 5Department of Public Health, School of Public Health, Maragheh University of Medical Sciences, Maragheh, Iran Abstract Background and Objectives Thalassemia major is an autosomal recessive disease with serious morbidity, mortality and pathology. Due to today’s therapeutic advances, the life expectancy of thalassemia patients has significantly increased. As a result, thalassemia patients need lifelong care, but caring for patients with thalassemia causes a lot of costs. Therefore, being aware of the costs and effectiveness of the treatments is essential for controlling the costs and providing effective treatments. Materials and Methods In this cross-sectional descriptive study, a bottom-up method was used to estimate the treatment costs for thalassemia patients and all the costs were estimated over a one-year period (2015). The number of QALYs created by treatment was also extracted using the EQ5D questionnaire, and eventually, the Markov model was used to calculate the costs and effectiveness for patients’ longevity. Results Treatment for any patients with thalassemia major costs $ 8,321.8 per year. Applying a 3% discount rate, we estimated that each patient lifelong treatment costs $ 147,098.4, which would results in 11.8 QALYs. Hence, the cost per QALY would be $ 12,466,0. Conclusions Treating the patients with thalassemia major, despite its cost effectiveness, might cost a lot so that the treatment of the patients in the fourth decade of their lives may even reach the cost-effectiveness threshold. Therefore, increasing the costs in the field of patient screening and prevention of the birth of patients with thalassemia major seems to be useful. Key words: Cost-Benefit Analysis, beta-Thalassemia, Iran Received: 30 Apr 2018 Accepted:14 Aug 2018 Correspondence: Esmaeilzadeh F., PhD in Health Economics. Assistant Professor of Department of Public Health, School of Public Health, Maragheh University of Medical Sciences. Postal Code: 5515878151, Maragheh, Iran. Tel: (+9841) 37256926; Fax: (+9841) 37256901 E-mail: firooz.esmaeilzadeh@gmail.com
Authors and Affiliations
S. Emamgholipour, B. Ahmadi, A. Rajabi, A Azarkeivan, M. Ebrahimi, F. Esmaeilzadeh
Keywords
Related Articles
- EP ID EP522334
- DOI -
- Views 78
- Downloads 0
Understanding the Organizational Culture in Khorasan Razavi, Northern Khorasan, and Southern Khorasan Blood Centers based on Denison's Model
Understanding the Organizational Culture in Khorasan Razavi, Northern Khorasan, and Southern Khorasan Blood Centers based on Denison's Model Hoseyni M.1,2, Haddadi E.3, Rakhshani M.H.4 1Blood Transfusion Research Cen...
The number of the requests for, transfusion and the wastage of blood and blood components based on the ratio of the number of cross-matched blood to transfusion (C/T) in Semnan hospitals in 1394
The number of the requests for, transfusion and the wastage of blood and blood components based on the ratio of the number of cross-matched blood to transfusion (C/T) in Semnan hospitals in 1394 Rezaie M.1, Khaleghian...
Evaluation of bacterial contamination of platelet concentrates collected at Tehran Regional Blood Center
Evaluation of bacterial contamination of platelet concentrates collected at Tehran Regional Blood Center Ahmadi J.1(MD) ,Gholizadeh H.R 2(MS) , Farseh R.3(MS), Sharifi Sh.4(MD) 1Arad Hospital 2Iranian Blood Tra...
Detection of hepatitis B virus DNA (PCR) in HBsAg negative, anti-HBc positive blood donors in Tehran province
Detection of hepatitis B virus DNA (PCR) in HBsAg negative, anti-HBc positive blood donors in Tehran province Amini Kafi-abad S.1(MD), Talebian A.1(MD), Moghtadaie M.1(MSc), Ranjbar Kermani F.1(MSc), Ferdowsian F....
A Demand Forcasting Model for the Blood Platelet Supply Chain with Artificial Neural Network Approach and Arima Models
Background and Objectives One of the major issues in global healthcare systems is the issue of improving supply chain performance and uncertainties in demand. The aim of this study is to forecast blood platelet demand wi...